NEW YORK and CAESAREA, Israel, July
25, 2019 /PRNewswire/ -- Global digital therapeutics
innovator DarioHealth Corp. (Nasdaq: DRIO), today announced that
its CE certificate covers a USB-C connector enabled version of the
acclaimed Darioâ„¢ Blood Glucose Monitoring System. The USB-C
connector is used to transfer power and communication signals
between Android smart mobile devices and the Dario meter, and
ensures that consumers, beginning with the Europe market region, will receive the same
quality user experience with DarioHealth on the latest Android
smart phone devices.
Android smart mobile device manufacturers differentiate lines of
products across their markets aimed at different user populations,
with varying product specifications and product price points. The
USB-C connector standard is gradually gaining market share over its
main predecessor, the micro-USB, in smart mobile devices. By
focusing on high-end Android devices, Dario aims to extend its
footprint and have the widest market reach. The Dario Blood Glucose
Monitoring System is currently used with the Samsung Galaxy and LG
family smart mobile Android devices.
Erez Raphael, Chairman and CEO of
DarioHealth, commented, "Dario is always looking to stay ahead of
the curve and meet the latest technological developments in the
market head on. Current mobile technology is rapidly embracing the
USB-C standard and we have been working tirelessly to bring a
solution that accommodates this protocol. We are proud that our
organization has worked with speed and agility to ensure
connectivity to the latest Android devices. This significant
milestone will allow us to open a whole new market segment and
re-engage with former-Dario users who now have the newest Android
devices. This is a big breakthrough for us in the European market
as an estimated 60 million people have diabetes in Europe. Now more consumers in Europe can benefit from the Dario digital
therapeutics solution through their smartphone."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading Global Digital
Therapeutics (DTx) company revolutionizing the way people manage
their health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by precision data
analytics, high quality software, and personalized coaching,
DarioHealth have developed a novel approach that empowers
individuals to adjust their lifestyle in a unique and holistic
way.
DarioHealth's cross functional team operates at the intersection
of life science, behavioral science, and software technology to
deliver seamlessly integrated and highly engaging therapeutic
interventions. Already one of the highest rated diabetes solutions,
its user-centric approach is loved by tens of thousands of
customers around the globe. DarioHealth is rapidly expanding
solutions for additional chronic conditions such as hypertension
and moving into new geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that it by focusing on high-end Android devices, it aims to extend
its footprint and have the widest market reach, that the approval
of USB-C connector is a significant milestone that will allow it to
open a whole new market segment and re-engage with former-Dario
users who now have the newest Android devices and that more
consumers in Europe can benefit
from the Dario digital therapeutics solution through their
smartphone, it is using forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
+1-347-767-4220
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-usb-type-c-connector-for-the-european-android-market-is-ce-marked-300890918.html
SOURCE DarioHealth Corp.